



Epigenetics and Immune Checkpoints

Guest Editors:

Dr. Alessia Covre

Center for Immuno-Oncology,
Division of Medical Oncology and
Immunotherapy, Department of
Oncology, University Hospital of
Siena and University of Siena,
Siena, Italy.

Dr. Elisabetta Fratta

Immunopathology and Cancer
Biomarkers, Centro di
Riferimento Oncologico, Aviano,
Italy

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

The epigenetic immune modeling of cancer cells represents a key hallmark of cancer, as it impairs the host's functional immune recognition of malignant cells. The pharmacologic targeting of epigenetic alteration with epigenetic drugs has been demonstrated to possess significant immunomodulatory properties, sensitizing tumor cells to emerging immunotherapies.

It is essential to identify new mechanism(s) underlying treatment failure(s) and design novel epigenetic-based combination therapeutic approaches to overcome primary/secondary resistance. In addition, novel biomarkers for the prediction of the response to immune-checkpoint inhibitors are urgently needed to stratify cancer patients who would benefit most from this treatment. In this context, epigenetic biomarkers would represent a valuable tool to predict response to immunotherapy, thus offering more personalized therapeutic regimens. Therefore, our aim is to present a collection of the latest research regarding the role that epigenetics plays in improving cancer immunotherapy, and the utility in defining potential therapeutic targets and cancer biomarkers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at
Mount Sinai, Hess Center for
Science and Medicine, New York,
NY 10029, USA

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [ESCI \(Web of Science\)](#), [PMC](#), [PubMed](#), [Embase](#), [PubAg](#), [CAPlus / SciFinder](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*Biochemistry, Genetics and Molecular Biology (miscellaneous)*)

Contact Us

Epigenomes Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/epigenomes
epigenomes@mdpi.com
[X@Epigenomes](#)